Who are Moderna, Inc.'s main suppliers?

Moderna, Inc. (MRNA) key suppliers include: ARBUTUS, ARBUTUS-GENEVANT, GENEVANT, CARISMA-THERAPEUTICS, CYTOMX-THERAPEUTICS and 8 more. View the full supplier network at chainsifter.com/chain/MRNA.

Who are Moderna, Inc.'s major customers?

Moderna, Inc. (MRNA) key customers include: VERTEX-PHARMACEUTICALS-INCORPORATED, Vertex Pharmaceuticals Incorporated, FOREIGN-GOVERNMENTS, INTERNATIONAL-ORGANIZATIONS, Ares Capital Corporation and 16 more. View the full customer network at chainsifter.com/chain/MRNA.

What sector is Moderna, Inc. in?

Moderna, Inc. (MRNA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Moderna, Inc. Supplier List (MRNA): 13 Verified Suppliers

13Suppliers

21Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Moderna, Inc. (MRNA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

36Total relationships

4Distinct source URLs

12High confidence

0.756Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Moderna, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ARBUTUS	ARBUTUS	90%	Third-party royalties included $878 million related to the litigation settlement with Arbutus and Genevant, as well as amortization of the associated intangible asset.
ARBUTUS-GENEVANT	ARBUTUS-GENEVANT	90%	The Settlement Agreement includes a fully paid-up, royalty free, irrevocable, non-exclusive, worldwide license and covenant not to sue granted by Arbutus/Genevant to Moderna
GENEVANT	GENEVANT	90%	Third-party royalties included $878 million related to the litigation settlement with Arbutus and Genevant, as well as amortization of the associated intangible asset.
CARISMA-THERAPEUTICS	CARISMA-THERAPEUTICS	85%	We have entered into additional collaborations where we have agreed to provide funding in areas where we believe we can leverage our mRNA technology. These collaborations include those with: • Carism…
CYTOMX-THERAPEUTICS	CYTOMX-THERAPEUTICS	85%	We have entered into additional collaborations where we have agreed to provide funding in areas where we believe we can leverage our mRNA technology. These collaborations include those with: • CytomX…
NATIONAL-INSTITUTE-OF-ALLERGY-AND-INFECTIOUS-DIS	NATIONAL-INSTITUTE-OF-ALLERGY-AND-INFECTIOUS-DIS	80%	In December 2022, we entered into a non-exclusive patent license agreement with the National Institute of Allergy and Infectious Diseases (NIAID)
IMTX	Immatics N.V.	72%	Reciprocal relationship from IMTX graph: Reciprocal relationship from MRNA graph: tablished a global Environment, Health, and Safety (EHS) organization to foster a safe and healthy work environment w…
IMTX	Immatics N.V.	72%	tablished a global Environment, Health, and Safety (EHS) organization to foster a safe and healthy work environment with a focus on sustainability and compliance. Our approach integrates environmenta…
SNYNF	Sanofi	72%	at leads to shareholder value, broad eligibility for our equity programs further embeds our "We behave like owners" mindset and helps promote employee retention as these awards generally vest over a …
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from MRNA graph: at leads to shareholder value, broad eligibility for our equity programs further embeds our "We behave like owners" …
VRTX	Vertex Pharmaceuticals Incorporated	72%	Reciprocal relationship from VRTX graph: Reciprocal relationship from MRNA graph: tablished a global Environment, Health, and Safety (EHS) organization to foster a safe and healthy work environment w…
VRTX	Vertex Pharmaceuticals Incorporated	72%	tablished a global Environment, Health, and Safety (EHS) organization to foster a safe and healthy work environment with a focus on sustainability and compliance. Our approach integrates environmenta…
ROIV	Roivant Sciences Ltd.	62%	Reciprocal relationship from ROIV graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from ROIV graph: le patent applications at a reasonable cost or in a timely manner. Furthermo…

Moderna, Inc. Customers

Ticker	Name	Confidence	Evidence
VERTEX-PHARMACEUTICALS-INCORPORATED	VERTEX-PHARMACEUTICALS-INCORPORATED	92%	In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement) with Vertex Pharmaceuticals Incorporated
VRTX	Vertex Pharmaceuticals Incorporated	92%	Reciprocal relationship from VRTX graph: Reciprocal relationship from MRNA graph: In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement) with Vertex Pharmace…
FOREIGN-GOVERNMENTS	FOREIGN-GOVERNMENTS	90%	We sell our COVID vaccines, Spikevax and mNEXSPIKE, to the commercial market as well as to foreign governments and international organizations.
INTERNATIONAL-ORGANIZATIONS	INTERNATIONAL-ORGANIZATIONS	90%	We sell our COVID vaccines, Spikevax and mNEXSPIKE, to the commercial market as well as to foreign governments and international organizations.
ARCC	Ares Capital Corporation	72%	Reciprocal relationship from ARCC graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from ARCC graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from ARCC g…
ARCC	Ares Capital Corporation	72%	roviders. Wholesalers and distributors typically do not make upfront payments to us. In addition, we receive customer advance payments related to certain other revenue arrangements. As of March 31, 2…
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from MRNA graph: sease in birds known as avian influenza and poses a risk of spillover into the human population. The agreement also in…
AZN	AstraZeneca PLC	72%	sease in birds known as avian influenza and poses a risk of spillover into the human population. The agreement also includes additional options to prepare for and accelerate responses to future publi…
IMTX	Immatics N.V.	72%	er the greatest possible impact to people through mRNA medicines. COMMERCIAL We continue to build our differentiated commercial model, with active commercial subsidiaries in key markets across North …
IMTX	Immatics N.V.	72%	Reciprocal relationship from IMTX graph: Reciprocal relationship from MRNA graph: er the greatest possible impact to people through mRNA medicines. COMMERCIAL We continue to build our differentiated …
MRK	Merck & Co., Inc.	72%	ics. Among all variables, estimating returns continues to present the most significant judgment due to the broad range of potential outcomes and the lack of established return trends. While we now ha…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from MRNA graph: ics. Among all variables, estimating returns continues to present the most significant judgment due to the broad range…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from MRNA graph: ms are unsuccessful, or not as successful as others could have been, we may be unable to realize a sustainable retur…
SNYNF	Sanofi	72%	ms are unsuccessful, or not as successful as others could have been, we may be unable to realize a sustainable return on our investments and or achieve long-term growth. The vaccine market, and pharm…
VRTX	Vertex Pharmaceuticals Incorporated	72%	ics. Among all variables, estimating returns continues to present the most significant judgment due to the broad range of potential outcomes and the lack of established return trends. While we now ha…
AI-TECHNOLOGIES	AI-TECHNOLOGIES	62%	ully complied, with such laws, we could face substantial penalties. Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendatio…
ARBUTUS-BIOPHARMA-CORPORATION	ARBUTUS-BIOPHARMA-CORPORATION	62%	ith RNA encoding modified SARS-CoV-2 spike protein. We are subject to shareholder class action and shareholder derivative litigation pending in the U.S. District Court for the District of Massachuset…
CELLSCRIPT-LLC	CELLSCRIPT-LLC	62%	ith RNA encoding modified SARS-CoV-2 spike protein. We are subject to shareholder class action and shareholder derivative litigation pending in the U.S. District Court for the District of Massachuset…
GENERATION-BIO-CO	GENERATION-BIO-CO	62%	possible impact to people through mRNA medicines. COMMERCIAL We continue to build our differentiated commercial model, with active commercial subsidiaries in key markets across North America, Europe …
GENEVANT-SCIENCES-GMBH	GENEVANT-SCIENCES-GMBH	62%	ith RNA encoding modified SARS-CoV-2 spike protein. We are subject to shareholder class action and shareholder derivative litigation pending in the U.S. District Court for the District of Massachuset…
TAKEDA-PHARMACEUTICAL-COMPANY	TAKEDA-PHARMACEUTICAL-COMPANY	62%	ncial institution. Bank accounts in the United 109 States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC …

Moderna, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
MRNA-DEBT	Debt stack $591.0M	90%	Market cache reports total debt of $591.0M.

Moderna, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Moderna, Inc..

Moderna, Inc. Ownership

Holder	Name	Confidence	Evidence
MRNA-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 741 tracked holders.

Moderna, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
CCCC	C4 Therapeutics, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
DEO	Diageo plc	100.00	2
BNBX	BNB Plus Corp.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
CLYM	Climb Bio, Inc.	100.00	2
EVH	Evolent Health, Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2
IMMP	Immutep Limited	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
AZN	AstraZeneca PLC	100.00	1	['customer']

Moderna, Inc. Supply Chain